SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


 [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
     OF THE SECURITIES EXCHANGE ACT OF 1934.

                 For the quarterly period ended    January 31, 1996
                                                --------------------


                                       OR

 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES ACT OF 1934.

       For the transition period from                 to
                                      ---------------    -----------------


                         Commission file number 2-86360


                                INFORMEDICS, INC.
        (Exact name of small business issuer as specified in its charter)

                  Oregon                           93-0750571
          (State of incorporation)      I.R.S. Employer Identification No.)




         4000 Kruse Way Place, Bldg 3, Suite 210, Lake Oswego, OR 97035
           (Address  of  principal  executive offices)

                    Issuer's telephone number: (503) 697-3000

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the Securities  Exchange Act of 1934 during the preceding
12 months (or for such shorter  period that the issuer was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes X No

Number of shares of Informedics, Inc. $.01 par value common stock outstanding as
of March 1, 1996: 2,645,099.



<PAGE>





                                INFORMEDICS, INC.


                         Part I - Financial Information




          The   information   included  herein  is  unaudited.   However,   such
 information  reflects all adjustments  (consisting solely of normal,  recurring
 adjustments)  which are, in the  opinion of  management,  necessary  for a fair
 presentation of the results of operations for the interim periods.  The interim
 financial  information and notes thereto should be read in conjunction with the
 Company's  latest annual report on Form 10-KSB.  The results of operations  for
 the three  months  ended  January 31, 1996 are not  necessarily  indicative  of
 results to be expected for the entire year.


<PAGE>


INFORMEDICS,  INC.
------------------
STATEMENTS OF OPERATIONS
------------------------

<TABLE>
<CAPTION>

                                                                     Three Months Ended January 31,
                                                                 ------------------------------------------
                                                                        1996                   1995

                                                                 ------------------------------------------

<S>                                                                     <C>                    <C>

REVENUE:
Product Sales                                                           $  426,880             $  618,766
Customer Service and Support                                               857,301                841,443
                                                                 -------------------     ------------------

Total Revenue                                                            1,284,181              1,460,209
                                                                 -------------------     ------------------

COSTS AND EXPENSES:
Cost of Products Sold                                                      233,825                176,595
Cost of Customer Service and Support                                       714,205                592,374
Selling & Administrative Expenses                                          634,646                476,642
Depreciation & Amortization                                                 87,198                188,410
                                                                 -------------------     ------------------

Total Costs and Expenses                                                 1,669,874              1,434,021
                                                                 -------------------     ------------------

Operating Income  (Loss)                                                 (385,693)                 26,188
                                                                 -------------------     ------------------

OTHER INCOME (EXPENSE):
Interest Expense                                                               (7)                  (255)
Interest Income                                                              4,104                 12,733
Other Income (Expense)                                                       (214)                    823
                                                                 -------------------     ------------------

Total Other Income                                                           3,883                 13,301
                                                                 -------------------     ------------------

INCOME  (LOSS) BEFORE INCOME TAXES                                       (381,810)                 39,489

INCOME TAX PROVISION                                                     (145,963)                  7,883
(BENEFIT)
                                                                 -------------------     ------------------

NET INCOME (LOSS)                                                     $  (235,847)              $  31,606
                                                                 ===================     ==================

Weighted Average Number of Common
  Shares Outstanding and Common Stock
  Equivalents Outstanding                                                2,643,404              2,836,897
                                                                 ===================     ==================




  EARNINGS (LOSS) PER SHARE                                         $       (0.09)          $        0.01
                                                                 ===================     ==================

</TABLE>

 See Note to Financial Statements.


<PAGE>


INFORMEDICS, INC.
-----------------
BALANCE SHEETS
--------------

<TABLE>
<CAPTION>


                                                                       January 31,            October 31,
ASSETS                                                                   1996                    1995
                                                                    ----------------       ---------------
<S>                                                                     <C>                    <C>


CURRENT ASSETS:

Cash                                                                    $  578,624             $  534,260
Accounts Receivable, less allowance
   for doubtful accounts of $ 92,623  in
   1996 and $ 64,623 in 1995                                               877,241                807,984
Inventories                                                                 74,236                 74,272
Prepaid Expenses and Other Current Assets                                   76,946                104,378
Income Taxes Receivable                                                     57,736                 86,823
Deferred Income Taxes                                                      248,834                254,804
                                                                    ----------------       ----------------

Total Current Assets                                                     1,913,617              1,862,521
                                                                    ----------------       ----------------


FIXED ASSETS:

Furniture and Fixtures                                                     135,470                132,830
Machinery and Equipment                                                    648,273                597,175
Automobiles                                                                 29,138                 29,138
Leasehold Improvements                                                      20,142                 20,142
Other Fixed Assets                                                         119,880                118,009
                                                                    ----------------       ----------------
                                                                           952,903                897,294
Less accumulated depreciation and amortization                             628,993                581,259
                                                                    ----------------       ----------------

Total Fixed Assets                                                         323,910                316,035
                                                                    ----------------       ----------------

OTHER ASSETS:

Software Development Costs,
   less accumulated  amortization of $ 458,201 in
   1996 and $ 1,464,073 in 1995                                            666,826                576,433
Purchased Software,
   less accumulated amortization of $ 226,804 in 1996
   and  in 1995                                                                ---                    ---
Covenants Not to Compete,
   less accumulated amortization of $  429,540 in 1996
   and $ 410,249 in 1995                                                    64,505                 83,796
Deferred Income Taxes                                                      406,500                253,907
Other                                                                       41,816                 45,252
                                                                    ----------------       ----------------

Total Other Assets                                                       1,179,647                959,388
                                                                    ----------------       --------------

TOTAL ASSETS                                                          $  3,417,174           $  3,137,944
                                                                    ================       ================
</TABLE>

See Note to Financial Statements


<PAGE>


INFORMEDICS, INC.
-----------------
BALANCE SHEETS
--------------
<TABLE>
<CAPTION>



                                                                         January 31,               October 31,
   LIABILITIES AND STOCKHOLDERS' EQUITY                                     1996                      1995
                                                                       ---------------        ---------------
<S>                                                                       <C>                    <C>


   CURRENT LIABILITIES:

   Accounts Payable and Accrued Expenses:
      Trade Accounts                                                      $  171,470             $  215,354
      Customer Deposits                                                       77,790                 25,923
      Accrued Wages, Payroll Taxes and Employee                              195,940                183,945
         Benefits
      Other Accrued Liabilities                                               17,197                  6,270
   Deferred Revenue                                                        1,648,138              1,163,903
   Current Portion of Long-Term
      Obligations                                                             13,033                 13,033
                                                                       ---------------        ------------------

   Total Current Liabilities                                               2,123,568              1,608,428

   LONG-TERM OBLIGATIONS:

   Deferred Rent                                                              40,186                 43,444
                                                                       ---------------        ---------------

   Total Current Liabilities and
      Long-Term Obligations                                                2,163,754              1,651,872
                                                                       ---------------        ---------------

   STOCKHOLDERS' EQUITY:

   Common Stock, $.01 par value:
      authorized 10,000,000 shares;
      shares outstanding:   2,645,099 in 1996 and 2,642,207                   26,451                 26,422
      in 1995
   Capital in Excess of Par Value                                          1,908,642              1,905,476
   Note Receivable from Stockholder                                         (22,000)               (22,000)
   Accumulated Deficit                                                     (659,673)              (423,826)
                                                                       ---------------        ---------------

   Total Stockholders' Equity                                              1,253,420              1,486,072
                                                                       ---------------        ---------------

   TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY                                                            $  3,417,174           $  3,137,944
                                                                       ===============        ===============

</TABLE>

See Note to Financial Statements.



<PAGE>


INFORMEDICS, INC.
-----------------
STATEMENTS OF CASH FLOWS
------------------------

<TABLE>
<CAPTION>
                                                                               Three Months Ended January 31,
                                                                       -----------------------------------------
                                                                               1996                   1995
                                                                       -----------------      ------------------
<S>                                                                        <C>                       <C>

CASH FLOWS FROM OPERATING ACTIVITIES:

  Net income (loss)                                                        $  (235,847)              $  31,606

ADJUSTMENTS TO RECONCILE NET
INCOME (LOSS) TO NET CASH PROVIDED
BY OPERATING ACTIVITIES:
 Depreciation and Amortization                                                   87,198                188,410
 Provision for losses on accounts receivable                                     28,000                  5,000
 Deferred Income Taxes                                                        (146,623)               (25,119)
 Tax benefits from stock options exercised                                          650                    ---
 Changes in Assets and Liabilities:
   Accounts Receivable                                                         (97,257)              (230,201)
   Income taxes receivable                                                       29,087               (11,254)
   Inventories                                                                       36               (38,514)
   Prepaid Expenses and Other Current Assets                                     27,432               (15,323)
   Accounts Payable and Accrued Expenses                                         30,905                 65,580
   Income Taxes Payable                                                             ---               (19,744)
   Deferred Revenue                                                             484,235                423,384
   Deferred Rent                                                                (3,258)                 58,832
                                                                       ------------------     ------------------
Net cash provided by operating activities                                       204,558                432,657
                                                                       ------------------     ------------------

INVESTING ACTIVITIES:
 Property additions                                                            (55,609)               (79,487)
 Capitalized software development costs                                       (110,566)               (88,370)
 Other                                                                            3,436                 33,771
                                                                       ------------------     ------------------
 Net cash used for investing activities                                       (162,739)              (134,086)
                                                                       ------------------     ------------------
                                                                                              
FINANCING ACTIVITIES:
 Proceeds from issuance of common stock                                           2,545                    ---
                                                                       ------------------     ------------------
 Net cash provided by financing activities                                        2,545                    ---
                                                                       ------------------     ------------------

NET INCREASE IN CASH                                                             44,364                298,571

CASH AT BEGINNING OF QUARTER                                                    534,260              1,055,378
                                                                       ------------------     ------------------

CASH AT END OF QUARTER                                                        $ 578,624           $  1,353,949
                                                                       ==================     ==================


</TABLE>

<PAGE>


INFORMEDICS, INC.
-----------------
STATEMENTS OF CASH FLOWS
------------------------

<TABLE>
<CAPTION>

                                                                    Three Months Ended January 31,
                                                                 --------------------------------------
                                                                   1996                  1995
                                                                 --------------------------------------
<S>                                                              <C>                    <C>   

                             
Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                                        $      7              $   255
 Income Taxes  Paid (Received)                                    (29,077)              64,000



</TABLE>



See Note to Financial Statements.



<PAGE>


INFORMEDICS, INC.
-----------------
NOTE  TO FINANCIAL STATEMENTS
-----------------------------


1.        SIGNIFICANT ACCOUNTING POLICIES

          INDUSTRY SEGMENT
          ----------------

          The Company derives its revenue solely from the sales and servicing of
          microcomputer software and related hardware.

          INVENTORIES
          -----------

          Inventories  are  stated  at the  lower  of cost or  market.  Specific
          identification is used to determine the costs of hardware and software
          inventory.

          FIXED ASSETS
          ------------

          Fixed assets are stated at cost,  less  accumulated  depreciation  and
          amortization.  The  costs of fixed  assets  are  depreciated  over the
          estimated  useful  lives (two to five  years) of the assets  using the
          straight-line  method.  Leasehold  improvements are amortized over the
          term of the lease (five years).

          CUSTOMER SERVICE AND SUPPORT REVENUE
          -----------------------------------

          Customer  service and support revenue  represents  revenue earned from
          hardware and software maintenance contracts, training, installation of
          new systems,  and general  software  support and programming  services
          provided to customers.  Under  renewable  maintenance  contracts,  the
          Company  provides,  for a term of  generally  not more  than one year,
          essentially all maintenance and repairs  resulting from the normal and
          intended  use  of  its  products.   Deferred  revenue  on  maintenance
          contracts is amortized  by the  straight-line  method over the life of
          the contracts.

          REVENUE RECOGNITION
          -------------------

          Revenue from sales of software and hardware is generally recorded when
          the product is shipped.  Revenue from custom software products,  which
          are  marketed  to  customers   primarily   under   perpetual   license
          arrangements,  is recorded at the time the  product is  installed  and
          accepted by the customer. Revenue from services other than maintenance
          contracts is recognized as performed.

          INCOME TAXES
          ------------

          Income taxes are accounted for using the  methodology  established  by
          Statement  of   Financial   Accounting   Standards   (SFAS)  No.  109,
          "Accounting for Income Taxes", which requires an asset and a liability
          approach to  financial  accounting  and  reporting  for income  taxes.
          Deferred   income  tax  assets  and   liabilities   are  computed  for
          differences  between the  financial  statement and tax bases of assets
          and liabilities  that will result in taxable or deductible  amounts in
          the future.  A valuation  allowance is  established  when necessary to
          reduce deferred tax assets to amounts expected to be realized based on
          enacted  tax laws and rates  applicable  to the  periods  in which the
          differences are expected to affect taxable income.  Income tax expense
          is the tax payable or  refundable  for the  period,  plus or minus the
          change during the period in deferred tax assets and liabilities.



<PAGE>


INFORMEDICS, INC.
-----------------
NOTE TO FINANCIAL STATEMENTS
----------------------------



          SOFTWARE DEVELOPMENT COSTS
          --------------------------

          Certain software development costs are being capitalized and amortized
          over the estimated  economic life of the software,  on a straight-line
          method,  commencing  when each product or enhancement is available for
          general release.  Amortization using the straight-line  method for the
          three-month  periods  ended January 31, 1996 and 1995 was $ 20,173 and
          $100,639, respectively.

          In 1995, the Company  changed its practice for estimating the economic
          life  of  a  software  product.  For  software  released  for  general
          distribution on or after February 1, 1995, the estimated economic life
          of the software is two years or the period  until a new major  release
          of the software is expected to be distributed, whichever is shorter.

          PURCHASED SOFTWARE
          ------------------

          Purchased  software  is  stated  at  cost  and  was  amortized  on the
          straight-line method over its estimated useful life.  Amortization for
          the three-month period ended January 31, 1995 was $ 16,630.  Purchased
          software was fully amortized at October 31, 1995.

          COVENANTS NOT TO COMPETE
          ------------------------

          Covenants  not to  compete  are stated at the  estimated  value of the
          consideration given for the covenants  (including the present value of
          any future payments to be made under each agreement), less accumulated
          amortization. The costs of the covenants are being amortized over four
          or seven years, using the straight-line method.  Amortization for each
          of the  three-month  periods  ended  January  31,  1996 and 1995 was $
          19,291.

          EARNINGS (LOSS) PER SHARE
          -------------------------

          Earnings  (loss)  per share  are  computed  on the  basis of  weighted
          average  number of shares  outstanding  plus common stock  equivalents
          which would arise from the  exercise  of stock  options and  warrants.
          Common stock equivalents are excluded from the calculation of net loss
          per  share  for three  months  ended  January  31,  1996,  as they are
          antidilutive.

          CASH AND CASH EQUIVALENTS
          -------------------------

          The Company considers cash on hand, deposits in bank and highly liquid
          debt  instruments  purchased  with  original  maturity  dates of three
          months or less, as cash.

          RECLASSIFICATIONS
          -----------------

          Certain  prior year amounts have been  reclassified  to conform to the
          current year presentation.  These  reclassifications have no effect on
          net income.


<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

HIGHLIGHTS

During  the  first  quarter  of 1996,  the  Company  continued  to invest in the
development of its software products.  As a result the Company incurred software
development  costs of  $384,393  for the  first  quarter  of 1996,  compared  to
$274,115 for the first quarter of 1995. Of the total costs incurred, the Company
capitalized  $110,566 for the first quarter of 1996, compared to $88,370 for the
first quarter of 1995.  New software  products in which the Company  invested in
1996  included  a Windows  version  of a managed  care  system  for  independent
physician  associations  and a Windows version of the Company's lab test request
system.  During the first  quarter of 1996,  the  Company  also  invested in the
enhancement of its LifeLine and ClinicManager software products.

A decrease  in the number of the  Company's  laboratory  software  systems  sold
resulted in a decrease of $191,886 or 31% in product sales for the first quarter
of 1996 when compared to the first  quarter of 1995.  The Company feels that the
number of laboratory systems sold in first quarter 1996 was negatively  impacted
by the Food & Drug  Administration's  (FDA)  decision to regulate all blood bank
software  developers.  Although  the  Company  was one of the first  blood  bank
software companies to prepare and file a required pre-market notification (510k)
report with the FDA, the Company  believes that potential  customers are waiting
to see how blood bank software  vendors  respond to the additional  regulations.
The Company feels its prompt filing of the 510k will benefit the Company's sales
in future quarters.

During the first quarter of 1996,  the Company also  increased its investment in
the sales and marketing of its products by adding sales and marketing staff. The
costs  associated  with the  additional  staff  contributed  to the  increase in
selling and  administrative  costs,  from  $476,642  for first  quarter  1995 to
$634,646 for first quarter 1996.

Lower product sales, and the increased investment in the development of software
and in sales  and  marketing  resulted  in a net loss of  $235,847  or $0.09 per
share, in the first quarter 1996, compared to net income of $31,606 or $0.01 per
share, in the first quarer 1995.

RESULTS OF OPERATIONS - MATERIAL CHANGES

As stated  earlier,  the  decrease in product  sales of $191,886 or 31% in first
quarter 1996,  compared to first  quarter 1995,  resulted from a decrease in the
number of laboratory  systems sold. The number of physician  office systems sold
was  approximately the same in the first quarter of 1996 as in the first quarter
of 1995.

 An increase in first quarter 1996  hardware  sales,  primarily  relating to the
physician office products, resulted in an increase in the cost of products sold.
As a percentage of hardware  sales,  cost of products sold increased from 80% in
first quarter 1995 to 82% in first quarter 1996.

Cost of customer service and support  increased by $121,831 or 21% for the first
quarter  of 1996  when  compared  to the first  quarter  of 1995.  The  increase
resulted from an increase in the software  development  costs that were expensed
rather than  capitalized  and from costs  incurred  for the first  quarter  1996
distribution  of an enhanced  version of the  Company's  LifeLine  product.  The
increase  in the  amount  of  software  development  costs  that  were  expensed
primarily relates to the development of new software products.

The increase in selling and administrative expenses of $158,004 or 33% for first
quarter  1996  primarily  resulted  from an increase in the sales and  marketing
staff, as discussed earlier.  Additionally,  the Company increased its allowance
for bad debts and wrote-off some pre-paid royalty fees.


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS-CONTINUED


The  decrease in  depreciation  and  amortization  expense of $101,212 for first
quarter  1996  when  compared  to first  quarter  1995,  resulted  from the 1995
write-down  and  reduction  in  economic  lives  of  capitalized  and  purchased
software.

LIQUIDITY - CAPITAL RESOURCES

The Company's financial condition remains strong. The Company's cash position on
January 31, 1996 was  $578,624,  compared  to $534,260 on October 31,  1995.  An
increase in the deferred revenue  liability on January 31, 1996 when compared to
October 31, 1995,  resulted in a negative working capital of $209,951 on January
31, 1996.  Excluding the deferred  revenue  liability,  which is a liability for
future  services,  the  Company's  working  capital  on  January  31,  1996  was
$1,438,187.

Net cash provided by operations of $204,558 was sufficient to cover the net cash
used to acquire  additional  assets and fund the  development  of the  Company's
software in the first quarter of 1996.

Capital  expenditures  for property  additions  were $55,609 and $79,487 for the
first quarter of 1996 and 1995,  respectively.  Capitalized software development
costs  were   $110,566  and  $88,370  for  the  first  quarter  1996  and  1995,
respectively.  Management expects 1996 expenditures for property additions to be
less  than  1995  amounts.  Management  anticipates  that  capitalized  software
development costs will be somewhat lower for the remainder of 1996 when compared
to 1995. All such  expenditures  are expected to be funded through cash provided
by operations and from the Company's current cash position.

The  Company  has a  $700,000  uncommitted  revolving  line of  credit  with the
Company's bank. All of the assets of the Company are pledged as security for the
line of credit.  Terms of the  revolving  line of credit  require the Company to
maintain certain financial ratios. As of the date of this Quarterly Report,  the
Company has not  borrowed  under the line of credit and has obtained a waiver of
its noncompliance for one of the specified financial ratios. The line of credit,
which is renewed  annually,  has been in place  since  1992.  The line of credit
expires April 15, 1996.



<PAGE>


                                INFORMEDICS, INC.

                           Part II - Other Information



 Item 6.   Exhibits and Reports on Form 8-K

          (a)  Exhibits.

               4(a)  Articles  IV,  VI  and  VII  of the  Restated  Articles  of
                     Incorporation, as amended (1)

               4(b)  Articles  1, 2, 5, 7, 8 and 9 of the  Restated  Bylaws,  as
                     amended (2)

               4(c)   Form  of   Indemnification   Agreement--Directorship   and
                      Officership Agreement (3)


               27   Financial Data Schedule

          (b)  Reports on Form 8-K.  During the quarter  ended  January 31,
               1996, the Company filed no reports on Form 8-K.



-------------------------------------------------------


         (1)    Incorporated by reference to the Company's  annual report on
                Form 10-K for the year ended October 31, 1993.

         (2)   Incorporated by reference to the Company's  annual report of Form
               10-Q for the quarter ended April 30, 1993.

         (3)   Incorporated  by  reference  to the  Company's  definitive  proxy
               material  filed with the  Securities  and Exchange  Commission on
               April 28, 1988.



<PAGE>



                                   SIGNATURES



Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                   INFORMEDICS, INC. (Registrant)


Date March 14, 1996                By /s/ John Tortorici
     --------------------------       -----------------------------
                                      John Tortorici
                                      Principal Executive Officer



Date March 14, 1996                By /s/ Dale E. Conner
     --------------------------      ------------------------------
                                     Dale E. Conner, Vice President
                                      and Chief Financial Officer







<PAGE>

                                  FORM 10-QSB

                                 Exhibit Index



Exhibit                                                       
-------                                                       

     27   Financial Data Schedule